Modern Approaches for Optimal Management of Dry Eye Disease : Episode 12

Emerging Therapies for Dry Eye Disease

August 16, 2023

By William B. Trattler, MD
Crystal Brimer, OD, FAAO

Opinion

Video

Crystal Brimer, OD, and Kelly K. Nichols, OD, MPH, PhD, discuss two treatments, AZR-MD-001 and Reproxalap, that are in the pipeline to treat patients with dry eye disease (DED).

EP: 1.The Prevalence and Impact of Dry Eye Disease

EP: 2.The Impact of Dry Eye Disease on Coexisting Ocular Conditions

EP: 3.Clinical Perspectives on Standard Use of Dry Eye Disease Questionnaire

EP: 4.Diagnostic Tests for Dry Eye Disease

EP: 5.Dry Eye Treatment Approaches and the Use of Artificial Tears

EP: 6.Anti-Inflammatory Therapies for Dry Eye Disease

EP: 7.Factors to Consider in Choosing Anti-Inflammatory Therapies for Dry Eye Disease

EP: 8.Managing Patients With Dry Eye Disease Pre-Cataract or Refractive Surgery

EP: 9.Developing Treatment Algorithm for Dry Eye Disease.

EP: 10.Combining Procedural and Pharmacological Therapies in Dry Eye Disease

EP: 11.New FDA-Approved Therapies and Diagnostics for Dry Eye Disease

EP: 12.Emerging Therapies for Dry Eye Disease

EP: 13.Co-Management of Dry Eye Disease

EP: 14.Clinical Pearls for Management of Dry Eye Disease

Recent Videos

Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry

Alice Epitropoulos, MD, and Laura M. Periman, MD

Alice Epitropoulos, MD, and Laura M. Periman, MD

Alice Epitropoulos, MD, and Laura M. Periman, MD

Alice Epitropoulos, MD, and Laura M. Periman, MD

Alice Epitropoulos, MD, and Laura M. Periman, MD

Alice Epitropoulos, MD, and Laura M. Periman, MD

Alice Epitropoulos, MD, and Laura M. Periman, MD

Alice Epitropoulos, MD, and Laura M. Periman, MD

Related Content

FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED

FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Study looks at the correlation of humidity, temperature, and air pollutants on dry eye disease patients

Study looks at the correlation of humidity, temperature, and air pollutants on dry eye disease patients

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Novaliq receives positive CHMP opinion for ciclosporin 0.1% solution, Vevizye

Novaliq receives positive CHMP opinion for ciclosporin 0.1% solution, Vevizye

AG-80308 for dry eye disease on track for Phase 2 clinical trial

AG-80308 for dry eye disease on track for Phase 2 clinical trial

Related Content

FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED

FDA confirms acceptability of Palatin's remaining Phase 3 pivotal clinical trials for PL9643 in DED

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 4)

Study looks at the correlation of humidity, temperature, and air pollutants on dry eye disease patients

Study looks at the correlation of humidity, temperature, and air pollutants on dry eye disease patients

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Podcast: Modern approaches for the optimal treatment of dry eye disease (Part 3)

Novaliq receives positive CHMP opinion for ciclosporin 0.1% solution, Vevizye

Novaliq receives positive CHMP opinion for ciclosporin 0.1% solution, Vevizye

AG-80308 for dry eye disease on track for Phase 2 clinical trial

AG-80308 for dry eye disease on track for Phase 2 clinical trial

Terms and Conditions

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.